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ABSTRACT
Background. Both in animal models and in human
patients, pressurized intraperitoneal aerosol chemotherapy
(PIPAC) has been shown to improve local bioavailability
of chemotherapy in peritoneal nodules, as compared with
conventional peritoneal lavage. Pharmacokinetic studies
show a low drug concentration in peripheral venous blood.
However, hepatic and renal toxicities induced by delivering
chemotherapeutic drugs into the abdomen as a pressurized
aerosol have not yet been investigated.
Methods. Liver and renal function as well as toxicity
parameters were monitored after eight PIPAC applications
with doxorubicin (1.5 mg/m2 body surface) and cisplatin
(7.5 mg/m2 body surface) in three end-stage patients suf-
fering therapy-resistant peritoneal carcinomatosis. PIPAC
was repeated at 4-week intervals (three times in two
patients, twice in one patient). Peripheral venous blood was
collected preoperatively and then daily until the 5th post-
operative day, and sent to the hospital’s clinical chemistry
laboratory. Statistical analysis was performed by analysis
of variance (ANOVA).
Results. Gamma-glutamyltransferase was significantly ele-
vated (p \ 0.05) in the early postoperative phase. Glutamic
oxaloacetic transaminase [aspartate aminotransferase], glu-
tamic pyruvic transaminase [alanine aminotransferase], and
bilirubin levels were not influenced by the procedure. Quick-
test remained normal. Serum creatinine levels were not altered.
Conclusions. Under the above conditions, PIPAC did not
induce clinically relevant liver cytotoxicity. Liver metabolism
and function were not altered. Renal function remained within
the normal range. No cumulative toxicity was observed after
repeated PIPAC. PIPAC appears to be associated with very
limited hepatic and renal toxicity, which might be a signifi-
cant advantage over other administration routes.
In spite of significant progress in chemotherapy regimens,
peritoneal carcinomatosis (PC) still has poor prognosis and
remains an unmet medical need. Systemic chemotherapy is
the standard therapy in this palliative situation, but survival
benefit is limited, with for example median survival of
22 months in recurrent ovarian cancer and 16 months in
colorectal cancer.1–3 The limited results of chemotherapy are
explained in part by the mechanisms of chemoresistance in
these advanced tumors but also by poor penetration of the
therapeutic substance into tumor tissue.4,5
Over the last decade, locoregional delivery of chemother-
apy into the abdominal cavity has been increasingly applied
for treating PC, with the aim of increasing the drug concen-
tration ratio between tumor cells and plasma compartment.
This approach has been validated by pharmacological studies,
and more recently by clinical studies, for example, in ovarian
cancer and colorectal cancer.4,6–8
However, the efficacy of intraperitoneal chemotherapy is
impaired by two main pharmacological limitations, namely poor
penetration into tumor nodules and limited distribution within
the abdomen.6 Therefore, prior complete surgical cytoreduction
is required for effective intraperitoneal chemotherapy.9
Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
is an innovative technique, applying chemotherapeutic drugs
as a pressurized aerosol into the abdomen during laparos-
copy.10 In an animal model and ex vivo in surgical specimens,
PIPAC has been shown to improve the local bioavailability of
drug and staining substances, as compared with conventional
peritoneal lavage.11,12 Recently, this excellent bioavailability
in the nodules of PC has been confirmed in human patients,
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and pharmacokinetic analysis showed a low drug concentra-
tion in peripheral venous blood.13
While these results are encouraging, it remains unclear
whether PIPAC causes significant hepatic or renal toxicity.
In theory, local drug delivery into the abdomen combined
with the artificial intraabdominal pressure might increase the
risk for first-pass hepatic toxicity and direct toxic renal
parenchymal injury. Herein we report data on liver and renal
toxicity from a pilot study of patients subjected to PIPAC.
PATIENTS AND METHODS
Study Design
This is a prospective data collection (phase 0 study)
within the framework of individual compassionate use of
an experimental therapy as defined by article 41 nr. 2 ff
AMG (German Arzneimittelgesetz). The procedures were
performed at the Evangelisches Krankenhaus Bielefeld and
at Marienhospital, Ruhr-University Bochum, Germany.
Ethics
The protocol was approved by the Institutional Review
Board (Ethikkommission der WW-Universita¨t Mu¨nster and
Medical Chamber of Westfalia-Lippe). The patients were
extensively informed about the procedure and included in
the study if they gave their written consent. The procedures
were performed according to the Declaration of Helsinki
and EC and German laws and regulations. In particular,
occupational health safety risks were evaluated by two
independent audits (data on file).
Patients
Eight PIPAC procedures were performed in three patients
at 4–6-week intervals, between November 2011 and February
2012. Patient and disease characteristics are summarized in
Table 1.
Therapy
After insufflation of 12 mmHg capnoperitoneum, two
balloon trocars (12 mm and 5 mm; Applied Medical, Du¨s-
seldorf, Germany) were inserted into the abdominal wall.
Diagnostic laparoscopy was performed, and the possibility of
cytoreductive surgery excluded. Extent of peritoneal disease
was documented by video recordings in all quadrants, and
parietal biopsies were taken for anatomopathology, genomics
studies, and functional research. Ascites was removed, and the
volume documented. Then, a 10-mm nebulizer (Reger Med-
izintechnik, Rottweil, Germany) was connected to a high-
pressure injector (Injektron 82 M; MedTron, Saarbruecken,
Germany) and inserted into the abdomen. A pressurized aer-
osol containing cisplatin at a dose of 7.5 mg/m2 body surface
and doxorubicin 1.5 mg/m2 body surface was then applied via
the high-pressure injector and nebulizer. Therapeutic capno-
peritoneum (TC) was maintained for 30 min at body
temperature (37 C). Then, TC was exhausted using a closed
system including a particle filter into the waste air system of
the hospital. Finally, trocars were retracted and laparoscopy
ended. No drainage of the abdomen was applied. All surgical
procedures were performed by the same surgeon (M.A.R.).
Sampling
Peripheral venous blood was collected preoperatively
and then daily until the 5th postoperative day. Blinded
analysis was performed in the clinical chemistry laboratory
of our hospital according to routine protocols.
Statistical Analysis
Statistics were performed using SPSS version 14.0 software.
Descriptive statistics included mean, median, percentiles, and
TABLE 1 Patient
characteristics




Patient 1 Patient 2 Patient 3
Sex M M F
Age (years) 38 45 74
Cancer localization Gastric Appendiceal Ovarian













2 lines ? experimental 1 line 2 lines ? experimental
Reason for therapy
interruption
MDR Severe toxicity MDR
PIPAC sessions (n) 2 3 3
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confidence interval. Data are presented as box plots. Compar-
ative statistics over time were performed by one-way repeated
analysis of variance (ANOVA).
RESULTS
Discrete signs of liver toxicity were observed after
PIPAC with cisplatin 7.5 mg/m2 body surface and doxoru-
bicin 1.5 mg/m2 body surface (Fig. 1). First, we observed a
doubling of serum gamma-GT levels with a peak on the 4th
postoperative day (POD), followed by a decrease on POD 5
(one-way ANOVA, p = 0.22). Discrete liver cytolysis was
detected, with maximal GPT (ALAT) serum level of
135 ± 177 U/l on POD 4 versus a preoperative value
of 35 ± 31 U/l (p = 0.57). We also observed an increase of
GOT (ASAT) serum levels, with a peak of 76 ± 33 U/l on
POD 3 versus a preoperative value of 35 ± 8 U/l (p = 0.68).
Liver synthesis was also discretely impaired after
PIPAC application. Quick-test dropped from 103 ± 8 %
(preoperatively) to 84 ± 2 % on POD 4. However, the
mean values remained within the normal range (70–100 %)
(Fig. 1). Total bilirubin serum levels remained within the
normal range, increasing slightly on POD 1 and then
returning to the preoperative value within 4 days.
Renal function was not impaired: Serum creatinine
levels remained within the normal range (Fig. 2), with a
peak of 0.75 ± 0.19 mmol/l on POD 1 versus a preoper-
ative mean value of 0.70 ± 0.17 mmol/l.
No cumulative toxicity was observed after repeated
PIPAC application at 4-week intervals. All three patients
received PIPAC twice or three times. The preoperative
mean serum creatinine level was not increased, as com-
pared with the reference value before the first application,
so that cumulative renal injury could be reasonably
excluded (Fig. 2). A similar pattern was observed for liver
toxicity: serum GOT, GPT, and bilirubin as well as Quick-
test did not increase significantly with repeated NIPAC
application (data not shown)
FIG. 1 Liver toxicity: discrete liver toxicity was observed after
PIPAC, with increase of serum gamma-GT levels (ANOVA,
p \ 0.05). No liver cytolysis was detected, with GOT (ASAT) and
GPT (ALAT) remaining within the normal range. ANOVA: repeated
analysis of variance. Normal values: gamma-GT 9–36 U/l; GOT
(ASAT) 5–31 U/l; GPT (ALAT) 0–34 U/l. Liver function: Liver
metabolism was not significantly impaired after PIPAC application.
Liver synthesis function, as monitored by Quick-test, remained within
the normal range. ANOVA: repeated analysis of variance. Normal
values: alkaline phosphatase 40–150 U/l; total bilirubin \1.2 mg/dl;
Quick 70–120 %. Green shaded areas = normal range of measured
parameters
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DISCUSSION
These pilot data obtained in the first patients treated with
PIPAC worldwide show that, with the drugs above and
with the dose range tested, PIPAC did not induce signifi-
cant renal or hepatic toxicity. This is remarkable since
application of chemotherapy was repeated twice or three
times at 4-week intervals.
For hyperthermic intraperitoneal chemotherapy (HIPEC),
a combination of cisplatin and doxorubicin appears to be one
of the most effective available regimens with tolerable
locoregional toxicity. Currently, all patients with PC man-
aged at our institution with cytoreductive surgery (CRS) and
HIPEC are given doxorubicin and cisplatin. Pharmacologi-
cal aspects of intraperitoneal administration of these drugs
are well known: Doxorubicin shows a much more advan-
tageous plasma/peritoneal area under the curve (AUC) ratio
than cisplatin (162 ± 113 and 20 ± 6, respectively). On the
other hand, very high intraperitoneal concentrations of cis-
platin can be achieved without inflicting significant systemic
toxicity. Penetration of the tumor mass is greater for cis-
platin than doxorubicin, as reviewed previously.14
After parenteral administration, cisplatin is present as an
unreactive, noncharged dichloride complex in the extracel-
lular space. This lack of electrical charge facilitates transport
across the vascular wall and the cellular membrane. Within
the cell, the chloride concentration is low (4 mmol/l) and the
chloride ions of the complex are exchanged by OH-groups
and free water molecules so that highly reactive water–
hydroxide–chloride complexes are formed. These com-
plexes have a toxic alkylating effect and cannot leave the
cell anymore because of their electric charge, eventually
causing cellular death. Cisplatin is mainly eliminated via the
kidney, so that hepatic side-effects of cisplatin are minimal.
In the kidney, the various metabolites of cisplatin reach high
local concentration, and the drug has dose-dependent renal
toxicity, as reviewed previously.15 In clinical practice and
with a standard systemic cisplatin regimen (75–100 mg/m2
body surface), tubular function is impaired in about 30 % of
patients, resulting in some cases in nonreversible tubular
necrosis and chronic renal failure.16 We have observed in
our patients comparable side-effects after HIPEC with cis-
platin doses over 75 mg/m2 body surface (unpublished
data). Parent platinum-based chemotherapeutics such as
carboplatin or oxaliplatin have the same mechanism of
action, but with a lower incidence of side-effects, as
reviewed previously.17
Doxorubicin belongs to the family of anthracyclines and
induces radical reactions (covalent binding to various
molecules) as well as formation of superoxide radical
anions (O2
–) and hydrogen peroxide (H2O2). In the process
of inactivation of these molecules, highly reactive and
toxic hydroxide radicals (OH–) are generated, which in turn
cause single- and double-strand DNA breaks, as reviewed
previously.15 Cellular death after doxorubicin therapy does
not occur by apoptosis, but is a sort of ‘‘dirty death’’ with
release of toxic metabolites into the surrounding tissue,
initiating a local chain reaction involving neighboring
cells. This explains why extravasation of doxorubicin
during intravenous delivery provokes extensive local tissue
necrosis. After parenteral application, tissue uptake of
doxorubicin is rapid, and elimination occurs mainly via
biliary excretion after hepatic metabolism. Interestingly,
doxorubicin has only moderate liver toxicity.18
During PIPAC, only about 10 % of a usual systemic
drug dose is applied into the abdomen. Moreover, systemic
FIG. 2 Renal function: serum creatinine levels did not increase
significantly (ANOVA) after PIPAC application and remained within
the normal range. ANOVA: repeated analysis of variance. Normal
value: 0.5–0.9 mg/dl. Cumulative renal toxicity of repeated PIPAC
with cisplatin 7.5 mg/m2 body surface and doxorubicin 1.5 mg/m2
body surface over 2–3 months of observation time. Preoperative
serum creatinine value before first PIPAC (three patients), second
(three patients), and third PIPAC (two patients). Creatinine levels
remain within the normal range. Normal value: 0.5–0.9 mg/dl. Green
shaded areas = normal range of measured parameters
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drug concentration is minimal, about 1 % of a systemic
dose or 5 % of a HIPEC dose.
However, the discussion should not be limited to the
dose applied but should also consider particular aspects of
PIPAC such as delivery in the immediate vicinity of target
organs, pressure application, and hemodynamic effects,
with the risk of inducing direct local toxicity.
The drug dose for our first experimental PIPAC protocol
was determined based on the dosage used for intravenous
delivery, with the assumption that systemic toxicity could not
be more pronounced than after intravenous delivery, since
systemic uptake cannot exceed 100 %. However, we were
concerned about possible local side-effects within the abdo-
men such as bowel necrosis, and decided to use the same
concentration in the chemotherapy solution as during HIPEC.
Since the maximal volume that can be nebulized during
PIPAC is about 200 ml, the total dose to be applied has to be
limited to about 10 % of a standard HIPEC dose. In light of
our first observations in human patients, it appears that this
cautious protocol design was probably life-saving since the
local bioavailability in PIPAC appears much higher than after
HIPEC. During PIPAC, chemotherapy is nebulized into the
peritoneal cavity under pressure of 12 mmHg. The rationale
for increasing the intraperitoneal pressure was to create a
gradient counteracting interstitial fluid pressure within
tumors. Since interstitial pressure is responsible for poor
penetration of chemotherapeutic drugs into tumors, bioavail-
ability is expected to be enhanced when the intraabdominal
pressure is artificially raised.5 This hypothesis has been con-
firmed in small-animal experiments, in a large-animal model,
as well as ex vivo on human specimen of PC.6,11,12 Our
results in vivo provide further proof that bioavailability in
tumor nodules is excellent after PIPAC, exceeding what can
be achieved with HIPEC (unpublished data).
A third topic of interest is that increasing the intraab-
dominal pressure impairs both portal and renal blood flow.
As a consequence, renal function is decreased during
capnoperitoneum, depending on the level of hydration,
intraabdominal pressure, patient positioning, and procedure
duration.19 An increase of the intraabdominal pressure by
5 mmHg (from 10 to 15 mmHg) resulted in a blood flow
decrease by 39 % to the liver and by 60 % to the perito-
neum. Splanchnic blood flow decreased along with operative
time, in spite of constant intra-arterial pressure.20 On the
basis of these data and our own observations, it appears
reasonable to propose that PIPAC is advantageous over
other delivery routes, because of limited blood inflow into
the intraabdominal organs during the uptake phase. This
results in limited outflow from the splanchnic circulation to
the systemic compartment, which leads to high tissue bio-
availability and low systemic plasma concentration. The
pharmacological data collected in the first patients confirm
that the systemic AUC of doxorubicin after PIPAC is only
about 1 % of that of systemic administration and 5 % of that
of HIPEC administration (unpublished data).
Finally, we did not observe any cumulative toxicity.
PIPAC can be applied several times without any difficulties,
since no therapy-related adhesions developed. This is indeed
an important feature for developing effective locoregional
chemotherapy regimen including several cycles and is a
clear advantage over HIPEC, for which repeated application
is exceptional. However, repeated administration of anthra-
cyclines is known to induce cumulative organ toxicity; For
example, application of doxorubicin is followed by severe
fibrosis induction, and cardiotoxic effects are known to
develop with a delay of up to 6 months, being irreversible
and eventually lethal. Thus, the maximal total dose of
doxorubicin applicable is limited to 550 mg/m2.15 In our
first patients, no signs of cumulative renal or hepatic toxicity
were observed after the second or third PIPAC administra-
tion. Moreover, no clinical symptoms of cardiac toxicity
were detected, in spite of the fact that one of the patients had
previously developed a life-threatening cardiac failure after
systemic administration of 5-fluorouracil (5-FU).
In conclusion, the first toxicity data obtained after PIPAC
are promising. No clinically relevant liver cytolysis was
observed, and neither metabolic nor synthetic hepatic func-
tions were significantly impaired. Renal function remained
within the normal range. PIPAC could be repeated without
inducing cumulative toxicity. Thus, it appears reasonable to
propose that PIPAC causes less hepatic and renal toxicity
than other chemotherapy delivery routes, due to lower ther-
apeutic doses and favorable kinetics. While promising, the
data presented here have to be considered as preliminary and
need to be confirmed in future studies including appropriate
dose-finding and safety studies in various cancer types and
with different chemotherapeutic drugs.
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